A PHASE-I STUDY OF ACIVICIN IN REFRACTORY PEDIATRIC SOLID TUMORS - A PEDIATRIC-ONCOLOGY-GROUP STUDY

Authors
BARUCHEL S BERNSTEIN M WHITEHEAD VM DEVINE S BELL B DUBOWY R GRIER H KRETSCHMAR C LANGEVIN AM VIETTI T
Citation
S. Baruchel et al., A PHASE-I STUDY OF ACIVICIN IN REFRACTORY PEDIATRIC SOLID TUMORS - A PEDIATRIC-ONCOLOGY-GROUP STUDY, Investigational new drugs, 13(3), 1995, pp. 211-216
Citations number
24
Categorie Soggetti
Pharmacology & Pharmacy",Oncology
Journal title
Investigational new drugs → ACNP
ISSN journal
01676997
Volume
13
Issue
3
Year of publication
1995
Pages
211 - 216
Database
ISI
SICI code
0167-6997(1995)13:3<211:APSOAI>2.0.ZU;2-S
Abstract
Forty-two patients with progressive solid tumors and brain tumors were entered in this Phase I study pf the glutamine antagonist acivicin gi ven intravenously over thirty minutes daily for five days. The major t oxicities encountered were myelosuppression and central nervous system toxicity (nightmares and somnolence). The maximum tolerated dosage on this schedule was 26 mg/M(2) daily for five days. Six patients includ ing three patients with brain tumor had stable disease.